Ena Respiratory’s preventative nasal spray treatment could reach human trials within four months, following results from an animal study released today which showed the spray reduced COVID-19 replication by up to 96%.
The drug discovery and pharma companies have extended their agreement to collaborate on development of new treatments for a range of therapeutic areas.
This month's spotlight on new hires, promotions and company acquisitions involves Elligo Health Research, PPD, Pfizer, Covance and other industry firms.
The company’s Sandoz division is offering 15 generic and OTC medicines to be sold at zero profit to low- and middle-income countries to treat the virus.
A leader from the healthcare solutions firm shares perspective on how application of advanced technologies has driven the evolution of the entire industry.
The agency continues to offer advice to pharma industry professionals during the global public health crisis, and offer advice on developing solutions.
The ninth annual event, taking place in Boston mid-November, will feature industry professionals addressing manufacturing practices, regulatory updates and market trends.
After receiving FDA approval, the pharmaceutical company has announced plans to launch a Phase I trial for an inhaled version of the COVID-19 treatment.
A leader with the industry association discusses the surging interest in harnessing artificial intelligence to advance various treatments and therapies.
The agency continues to offer advice related to drug development and clinical research during the pandemic, and take action against those falling out of line.
A representative of the research and development firm offers perspective on how the industry has shifted in recent years, thanks to a number of forces.
The pharmaceutical analysis firm is continuing its contract analytical laboratory services running, with changes designed to keep people and products safe.
With the acquisition of Weibel, SHL Medical looks to the development of novel drug delivery systems for self-administration, answering a need for improved patient-centricity in the sector.
Biohaven’s drug for acute treatment of migraine, manufactured using Catalent’s Zydis technology for orally disintegrating tablets, receives approval from the US FDA.
